Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | HTR1D | P28221 | 4/20 | 0.41 |
| ▸ | HTR1B | P28222 | 4/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CDK2 | P24941 | 1/20 | 0.41 |
| ▸ | KHK | P50053 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 5/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430546 | 0.84 | NCF1 (0.56) | HTR1AHTR1DHTR1BSLC6A4NCF1 | |
| SCHEMBL2881010 | 0.82 | CYP2C9 (0.50) | HTR1AHTR1DHTR1BSLC6A4KHK | |
| SCHEMBL429083 | 0.82 | CYP2C9 (0.50) | HTR1AHTR1DHTR1BSLC6A4KHK | |
| SCHEMBL4180251 | 0.82 | CYP2C9 (0.50) | HTR1AHTR1DHTR1BSLC6A4KHK | |
| SCHEMBL4181655 | 0.80 | NCF1 (0.60) | PIM2PIM1PIM3HTR1AHTR1D | |
| SCHEMBL4244446 | 0.76 | HTR6 (0.61) | HTR1AHTR1DHTR1BKHKADRA2A | |
| SCHEMBL4247868 | 0.76 | HTR6 (0.61) | HTR1AHTR1DHTR1BKHKADRA2A | |
| SCHEMBL4244450 | 0.76 | HTR6 (0.61) | HTR1AHTR1DHTR1BKHKADRA2A | |
| SCHEMBL14146963 | 0.74 | PRKCQ (0.59) | PIM2PIM1HTR1AHTR1DHTR1B | |
| SCHEMBL4247455 | 0.74 | MKNK1 (0.39) | PIM2PIM1PIM3MKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | GLAXO GROUP LIMITED (GB) | 2006-11-23 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264429-A1 | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | XDH, CYP4X1, PDHX | PIM2 4693/4885PIM1 4639/4885PIM3 4638/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | PIM2 3973/4885PIM1 4113/4885PIM3 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.